A study assessed treatments for myeloma, noting advancements in patient outcomes due to proteasome inhibitors and immunomodulatory drugs, yet acknowledging persistently poor results in high-risk cases marked by rapid disease progression.

Read More >https://multiplemyeloma.pocn.com/treatment/study-highlights-age-related-treatment-outcomes-in-myeloma-underscores-need-for-personalized-approaches/